People
-
Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in… Read more . . .
-
Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine… Read more . . .
-
CMO PharmaForm, a wholly-owned subsidiary of Akela Pharma, has hired J. Blair West, formerly of Bend Research and Azo Pharma, as Vice President of Pharmaceutical Operations. In addition, the company says, Feng Zhang will become… Read more . . .
-
Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson’s disease. The assets Civitas has licensed from Alkermes include a pipeline,… Read more . . .
-
Patrick G. LePore, President, CEO, and Chair of Par Pharmaceuticals will temporarily take over the reins at the company’s subsidiary Strativa Pharmaceuticals after Strativa’s President John A. MacPhee resigned. MacPhee was also Executive VP of… Read more . . .
-
The Defense Advanced Research Projects Agency (DARPA) has awarded a $5.7 million grant to Pulmatrix for development of inhaled cationic airway lining modulator (iCALM) products to protect military personnel and civilians against airborne diseases. Read… Read more . . .
-
William M. Wells has resigned as Chairman of the Board of Valeant Pharmaceuticals and has been replaced by Robert A. Ingram. Valeant subsidiary Biovail is co-devloping the Staccato loxapine inhaler with Alexza Pharmaceuticals. The FDA… Read more . . .
-
Richard Hawkins, who founded Pharmaco, now PPD Development, has joined the board of directors of Texas-based inhalation drug development company Savara. The company is developing a number of dry powder aerosol medicines based on its… Read more . . .
-
Thomas P. McCracken has joined MAP Pharmaceuticals as Vice President, Intellectual Property. MAP’s lead candidate, Levadex inhaled dihydroergotamine, is in Phase 3 trials, and McCracken will be responsible for the intellectual property program in support… Read more . . .
-
Dutch vaccine developer Mucosis has announced that John Lambert has been elected as the new chairman of its supervisory board. Mucosis is developing vaccines based on particles created from inactivated Lactococcus lactis bacteria, including its… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal